Dr Chin Tan Min

Consultant, Department of Haematology-Oncology, NUH

 

Education and Fellowships

MBBS, MRCP, NMRC research fellowship (Oncology Research Institute), HMDP (Massachusetts General Hospital Cancer Center)

 

Awards and Honours

• RISE award, 2008

• PI of grants awarded by NMRC, GCRC and SIG

 

Selected Publications

1. Clin Chem 2007. 53:1 Detection of epidermal growth factor variations by partially denaturing HPLC. Chin TM, D Anuar, R Soo, Manuel Salto-Tellez, WQ Li, B Ahmad, SC Lee, BC Goh,Kazauki Kawakami, B Iacopetta, R Soong. 
2. Clin Canc Res 2008; 14 (21) 6867-6876. Reduced erlotinib sensitivity of EGFR mutant non-small cell lung cancer following cisplatin exposure: A cell culture model of second-line erlotinib treatment Chin TM, M Quinlan, A Singh, Lecia V. Sequist, Thomas J Lynch, Daniel Haber, Sreenath V. Sharma, and Jeffrey Settleman 
3. J Thorac Oncol 2008 Sept 3(9):1077-8 Lung Cancer response to Gefitinib, then Erlotinib, then Gefitinib again. Alvin S. Wong, Kar-Yin Seto, Chin TM, Ross A. Soo 
4. Journal of thoracic oncology 2008. April 3 (4): 400-4 Evidence for Disease Control with Erlotinib after Gefitinib Failure in typical Gefitinib-Sensitive Asian Patients with Non-Small Cell Lung Cancer. Wong AS, Soong R, Seah SB, Chin TM, Ross Soo. 
5. Journal of Clinical Oncology Oct 2009 Fatal cystic change of brain metastases after response to geftinib in non-small cell lung cancer. YK Zee. Chin TM, A Wong 
6. How many lung adenocarcinomas come from bronchoalveolar carcinomas? Alvin Wong et al. Thoracic Cancer. 2 (2011) 54–60
7. J Chromatogr B Analyt Technol Biomed Life Sci. 2011 Jul 15;879(22):2155-61. Rapid determination of gefitinib and its main metabolite, O-desmethyl gefitinib in human plasma using liquid chromatography-tandem mass spectrometry. Wang LZ, Lim MY, Chin TM, Thuya WL, Nye PL, Wong A, Chan SY, Goh BC, Ho PC.